Two-year toxicity of simultaneous integrated boost in hypofractionated prone breast cancer irradiation: Comparison with sequential boost in a randomized trial

Radiother Oncol. 2021 May:158:62-66. doi: 10.1016/j.radonc.2021.02.010. Epub 2021 Feb 20.

Abstract

Introduction: A simultaneous integrated boost (SIB) leads to less acute toxicity. Less is known for late toxicity due to SIB. In this first and only randomized trial, two-years toxicity is analysed.

Materials and methods: Physician-assessed toxicity, using the LENT SOMA scale, and photographs, analysed with the BCCT.core software, was examined for 150 patients, randomized between SIB and sequential boost (SEB).

Results: Differences in physician-assessed two-years toxicity and photographic analysis between SIB and SEB are very small and not significant.

Conclusion: There is no indication that a SIB leads to an excess in toxicity or worse cosmetic outcome at 2 years.

Keywords: Breast cancer boost; Sequental boost; Simultaneous ingetrated boost.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / radiotherapy
  • Humans
  • Radiation Dose Hypofractionation
  • Radiotherapy, Adjuvant
  • Radiotherapy, Intensity-Modulated*